A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With MVA-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in HIV-1 Infected Adults on Suppressive ART
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Ad26 Mos4 HIV (Primary) ; MVA-Mosaic-HIV-vaccine-Janssen-Vaccines-and-Prevention (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
- 06 Nov 2018 Planned End Date changed from 16 Nov 2020 to 12 Feb 2021.
- 17 Jul 2018 Planned End Date changed from 12 Jun 2020 to 16 Nov 2020.
- 01 May 2018 Status changed from not yet recruiting to recruiting.